This site is intended only for healthcare professionals resident in India
Enbrel® is approved across 6 indications, including paediatric indications.¹
Enbrel® is among the approved and recommended biologics and small molecular therapies for PsA.1,3
Adapted from Lortholary O, et al. 2020; Enbrel® LPD. Version LPDENB062021.
Management of Patients With Active PsA4
Adapted from Singh JA, et al. 2019.
A PsA patient with metabolic syndrome
A JIA patient moving from childhood to adulthood
ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic drug; IL, interleukin; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NPF, National Psoriasis Foundation; PsA, psoriatic arthritis; TNF-α, tumour necrosis factor alpha; TNFi, tumour necrosis factor inhibitor.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022